Biotech Values

[poorgradstudent]

Avodart:

>Unfortunately for GSK, Avodart has only six more years to go before its patent expires in major markets.<

True.

But this is one of those pieces of news that makes me feel better with regards to my expectation that healthcare costs won't simply continue to skyrocket over time.

If they're reducing cancer incidence by 23% starting from the BPH stage with a drug that will be generic within a decade, I'd say that's great news for society in both the health and financial fronts.